Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts;
Division of Nephrology, University of California, San Francisco, San Francisco, California.
J Am Soc Nephrol. 2020 Mar;31(3):602-614. doi: 10.1681/ASN.2019090869. Epub 2020 Feb 13.
Leveraging quality metrics can be a powerful approach to identify substantial performance gaps in kidney disease care that affect patient outcomes. However, metrics must be meaningful, evidence-based, attributable, and feasible to improve care delivery. As members of the American Society of Nephrology Quality Committee, we evaluated existing kidney quality metrics and provide a framework for quality measurement to guide clinicians and policy makers.
We compiled a comprehensive list of national kidney quality metrics from multiple established kidney and quality organizations. To assess the measures' validity, we conducted two rounds of structured metric evaluation, on the basis of the American College of Physicians criteria: importance, appropriate care, clinical evidence base, clarity of measure specifications, and feasibility and applicability.
We included 60 quality metrics, including seven for CKD prevention, two for slowing CKD progression, two for CKD management, one for advanced CKD and kidney replacement planning, 28 for dialysis management, 18 for broad measures, and two patient-reported outcome measures. We determined that on the basis of defined criteria, 29 (49%) of the metrics have high validity, 23 (38%) have medium validity, and eight (13%) have low validity.
We rated less than half of kidney disease quality metrics as highly valid; the others fell short because of unclear attribution, inadequate definitions and risk adjustment, or discordance with recent evidence. Nearly half of the metrics were related to dialysis management, compared with only one metric related to kidney replacement planning and two related to patient-reported outcomes. We advocate refining existing measures and developing new metrics that better reflect the spectrum of kidney care delivery.
利用质量指标可以是一种强有力的方法,以确定影响患者预后的肾脏病护理中的实质性绩效差距。然而,指标必须具有意义、基于证据、可归因且可行,以改善护理提供。作为美国肾脏病学会质量委员会的成员,我们评估了现有的肾脏质量指标,并提供了质量衡量的框架,以指导临床医生和政策制定者。
我们从多个已建立的肾脏和质量组织中编制了一份全面的国家肾脏质量指标清单。为了评估这些措施的有效性,我们根据美国医师学院的标准进行了两轮结构化指标评估:重要性、适当的护理、临床证据基础、措施规范的清晰度以及可行性和适用性。
我们共纳入了 60 项质量指标,包括 7 项慢性肾脏病预防指标、2 项减缓慢性肾脏病进展指标、2 项慢性肾脏病管理指标、1 项晚期慢性肾脏病和肾脏替代规划指标、28 项透析管理指标、18 项广泛指标以及 2 项患者报告结局指标。我们确定,根据既定标准,29 项(49%)指标具有高度有效性,23 项(38%)具有中度有效性,8 项(13%)具有低度有效性。
我们将不到一半的肾脏病质量指标评为高度有效;其余指标的有效性较低,原因是归因不明确、定义和风险调整不足,或与最近的证据不一致。近一半的指标与透析管理有关,而只有一项与肾脏替代规划有关,两项与患者报告的结局有关。我们主张改进现有的指标并开发更好地反映肾脏护理提供范围的新指标。